Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HyMedPoly

Financiado

Cerrado

Drug Free Antibacterial Hybrid Biopolymers for Medical Applications

There is a general consensus that biomedical polymers of natural and synthetic origin should and will play a very important role in the development of new therapeutic strategies to treat diseases. Due to resistance of bacteria to... ver más

31/12/2018

LUCIDEON

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

LUCIDEON LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 9 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-12-31

MSCA-ITN-2014-EID: Marie Skłodowska-Curie Innovative T...

I+D

Cerrada hace 10 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

9 Participantes

LUCIDEON

0.00€ | Lider

KH VIVES

665.61K€ | Participante

UOW

1.09M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

INSAPANT Innovative tools to use south African plant extract in advan... 189K€ Cerrado

MAT2015-67648-R NANORECUBRIMIENTOS HIBRIDOS CON MEJORADA EFICIENCIA ANTIMICR... 121K€ Cerrado

BACATTACK A stealth attack tool for preventing clinical drug resistanc... 4M€ Cerrado

CTQ2015-74621-JIN DISEÑO DE BIOCIDAS INNOVADORES A PARTIR DE LA ELUCIDACION DE... 204K€ Cerrado

PEPTIDEBASEDHYDROGEL Toward the development of peptide based hydrogels for tissue... 235K€ Cerrado

MAT2013-42473-R DESARROLLO DE SISTEMAS AVANZADOS CON CAPACIDAD BACTERICIDA B... 220K€ Cerrado

Duración del proyecto: 48 meses Fecha Inicio: 2014-12-05
Fecha Fin: 2018-12-31

Líder del proyecto

LUCIDEON LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto There is a general consensus that biomedical polymers of natural and synthetic origin should and will play a very important role in the development of new therapeutic strategies to treat diseases. Due to resistance of bacteria to drugs, infection has become one of the toughest problems in the medical world as there are hardly any effective antibiotics left in the fight against many pathogens. This project aims to develop new therapies through a new combination of technology (a) development of new hybrid polymers with antibacterial functionality,(b) introduction of inhibitors that can permanently deactivate bacteriological proteases and (c) new formulations of bioactive ceramics and glasses that have specific charge potential to prevent bacterial growth. The challenge is to develop new medical polymers that have an intrinsic antibacterial functionality to achieve clinical effectiveness in the field. To develop the challenge to practical medical solutions, a new generation of industrial professionals is needed. They should have a solid multidisciplinary background complemented by the required academic and industrial experiences. The objective of this network is to train young PhD researchers to fill this demand in the strategic area of drug-free antibacterial hybrid biomedical polymers. This EID programme will achieve this by a joint training programme of world class academic and industrial institutes who will provide hands-on training in state of the art research projects related to key fundamental issues that determine the future new therapies of antibacterial biomaterials. The goal is to develop professionals that will play a pivotal role in pushing forward this challenging and knowledge-intense field for the coming decades to benefit the European economy, bring state-of-the-art technology to industry with advanced products for hospitals and personal health care and contribute to the development of therapeutic strategies to improve the quality of life.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores